WSD1720

WSD1720 is a brain-penetrant, small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) developed by Wayshine Biopharm. It is specifically engineered to cross the blood-brain barrier (BBB) with high efficiency, addressing a significant limitation of earlier-generation CDK4/6 inhibitors in treating central nervous system (CNS) malignancies. WSD1720 is currently being evaluated in clinical trials for the treatment of primary brain tumors, such as glioblastoma, and brain metastases arising from solid tumors like breast cancer. Its mechanism involves blocking the CDK4/6-mediated phosphorylation of the retinoblastoma (Rb) protein, which halts the cell cycle at the G1/S transition and suppresses tumor growth.